Coya Therapeutics to Join Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference

Coya Therapeutics, Inc. (NASDAQ: COYA), a Houston-based clinical-stage biotechnology company, has announced that its CEO, Howard Berman, Ph.D., along with Chief Business Officer and incoming CEO, Arun Swaminathan, Ph.D., will take part in a fireside chat at the Chardan 8th Annual Genetic Medicines Conference. This session is scheduled for Tuesday, October 1, 2024, at 2:00 pm ET, and will be moderated by Keay Nakae, a Senior Research Analyst at Chardan Capital Markets. The conference will be held between September 30 and October 1, 2024, at the Westin Grand Central in New York City. During the event, Drs. Berman and Swaminathan will also be available for one-on-one meetings.

Coya Therapeutics, Inc. is focused on developing biologics aimed at enhancing the function of regulatory T cells (Tregs) as potential treatments for systemic inflammation and neuroinflammation. Treg dysfunction is implicated in a range of diseases, including neurodegenerative, metabolic, and autoimmune disorders. This dysfunction can result in chronic inflammation and oxidative stress, disrupting the immune system's balance.

The company's pipeline of investigational products includes multiple therapeutic approaches designed to restore the anti-inflammatory and immunomodulatory functions of Tregs. These therapeutic platforms feature Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

The leading product in Coya's pipeline is COYA 302, a unique combination of COYA 301 (the company's proprietary low-dose IL-2) and CTLA4-Ig. This biologic is administered subcutaneously and targets Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia, Parkinson's Disease, and Alzheimer's Disease. COYA 302 employs a dual mechanism of action designed to increase the number and anti-inflammatory function of Tregs while simultaneously reducing the activity of microglia and the secretion of pro-inflammatory mediators. This multi-faceted approach aims to re-establish immune balance and reduce inflammation in a sustainable and durable fashion, which may not be achievable by either low-dose IL-2 or CTLA4-Ig alone.

Coya Therapeutics’ strategy involves leveraging the therapeutic potential of Tregs to address significant medical needs in various inflammatory and neuroinflammatory conditions. The company’s innovative approach aims to provide new treatments that offer long-lasting benefits for patients suffering from these challenging diseases.